MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Botulinum toxin: Clinical applications: spasticity"

  • MDS Virtual Congress 2020

    Identification of Factors that Impact Adherence to OnabotulinumtoxinA Treatment for Spasticity in Post-Stroke and Multiple Sclerosis Patients from ASPIRE

    A. Esquenazi, W. Feng, G. Wittenberg, P. Gallien, A. Baricich, K. Fanning, A. Zuzek, G. Francisco, D. Bandari (Elkins Park, PA, USA)

    Objective: Identify baseline clinical characteristics and treatment-related factors that impact adherence to onabotulinumtoxinA (onabotA) treatment in post-stroke and multiple sclerosis (MS) patients from the Adult…
  • MDS Virtual Congress 2020

    Perceptions of burden of spasticity and treatment satisfaction among post-stroke patients over the course of a botulinum neurotoxin A (BoNT-A) treatment cycle: An ethnographic study

    J. Jacinto, A. Lysandropoulos, A. Fulford-Smith (Estoril, Portugal)

    Objective: To design an ethnographic study following patients over a botulinum toxin type-A (BoNT-A) treatment cycle to inform individualized treatment. Background: The concept of individualized…
  • 2019 International Congress

    An examination of real-world onabotulinumtoxinA utilisation for the treatment of lower limb spasticity: The Adult Spasticity International Registry (ASPIRE) study

    A. Esquenazi, W. Jost, G. Bavikatte, D. Bandari, M. Munin, A. Zuzek, A. Patel, J. Largent, G. Francisco (Elkins Park, PA, USA)

    Objective: To explore real-world patterns of onabotulinumtoxinA utilisation in patients with lower limb spasticity over 2 years. Background: OnabotulinumtoxinA treatment for spasticity is variable as…
  • 2019 International Congress

    Goal setting for botulinum toxin injections: Impact of the Upper Limb International Spasticity (ULIS) programme

    K. Fheodoroff, S. Ashford, J. Jacinto, A. Brashear, P. Maisonobe, A. Lysandropoulos, L. Turner-Stokes (Hermagor, Austria)

    Objective: The Upper Limb International Spasticity (ULIS) programme is a series of observational cohort studies across >30 countries. This analysis explores changes in goal setting…
  • 2019 International Congress

    AbobotulinumtoxinA: evidence for long duration of response

    K. Foster, A. Lysandropoulos, P. Picaut (Abingdon, United Kingdom)

    Objective: To assess clinical treatment intervals and duration of response for abobotulinumtoxinA in the management of pediatric and adult spasticity and assess preclinical data that…
  • 2019 International Congress

    An examination of real-world onabotulinumtoxinA utilization for the treatment of upper limb spasticity: The Adult Spasticity International Registry (ASPIRE) study

    G. Francisco, G. Bavikatte, W. Jost, D. Bandari, S. Tan Tang, A. Zuzek, A. Patel, J. Largent, A. Esquenazi (Taoyuan, Taiwan)

    Objective: To explore real-world patterns of onabotulinumtoxinA utilization in patients with upper limb spasticity over 2 years. Background: OnabotulinumtoxinA treatment for spasticity is variable, as…
  • 2019 International Congress

    OnabotulinumtoxinA Reduces Disability in Treatment-Naive Adult Patients with Spasticity: Results from the ASPIRE Study

    W. Jost, A. Ellenbogen, G. Wittenberg, K. Ngo, J. Largent, A. Zuzek, G. Francisco, A. Esquenazi (Irvine, CA, USA)

    Objective: Examine real-world onabotulinumtoxinA utilization and effectiveness over 2 years in patients naive or non-naive to botulinum toxins for spasticity from the Adult Spasticity International…
  • 2019 International Congress

    Successful late rehabilitation based on botulinum therapy

    T. Kuznetsova, A. Svetkina (Samara, Russian Federation)

    Objective: Hemiparesis of various severity is the most common stroke side effect. On average 30-40% of stroke survivors develop post-stroke spasticity. The best neuroplasticity enabling…
  • 2019 International Congress

    Training and Usage of Botulinum Neurotoxin-A Guided Injection in Cervical Dystonia & Spastic Paresis: results from the INPUT survey

    R. Bhidayasiri, K. Bhatia, LJ. Jacinto, TM. Chung, A. Fulford-Smith, C. Colosimo (Roma, Italy)

    Objective: To describe the current situation of training and practices among physicians using guidance techniques for botulinum neurotoxin-A (BoNT-A) injectionsin the treatment of Cervical Dystonia…
  • 2019 International Congress

    Ixcellence Network®, an International Innovative Educational Programme To Improve Cervical Dystonia And Spastic Paresis Management: Feedback survey from 839 attendees

    C. Colosimo, TM. Chung, LJ. Jacinto, K. Bhatia, A. Fulford-Smith, R. Bhidayasiri (Roma, Italy)

    Objective: To assess the Ixcellence Network® training programme educative quality and impact on physicians using botulinum neurotoxin-A (BoNT-A) in cervical dystonia (CD) and spastic paresis…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley